Global Biologics Outsourcing Market Projected to Grow at 13.4% CAGR, Reaching $37.28 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Biologics Outsourcing Industry Market Size Be by 2025?
The market for outsourcing biologics services has seen swift expansion lately, projected to increase from a value of $20.06 billion in 2024 to $22.58 billion the following year, reflecting a compound annual growth rate of 12.6 percent; this upward trajectory during the past period is linked to factors such as escalating expenses related to research and development, mounting regulatory demands, the need for niche technical skills, and worldwide intercontinental business expansion.

What's the Long-Term Growth Forecast for the Biologics Outsourcing Market Size Through 2029?
Anticipated in the coming years is a swift expansion for the biologics outsourcing sector, projecting a valuation of $37.28 billion by 2029, driven by a compound annual growth rate (CAGR) of 13.4% throughout this projection window. This forward trajectory is fueled by several key factors such as the burgeoning of developing economies, the rise of individualized patient treatments, the formation of key collaborative partnerships, and the patent expiry of established biological medications. Concerning significant shifts anticipated during this forecast timeframe, these encompass forward strides in technological capabilities, the escalating intricacy of outsourcing specifications, the broadening landscape for biosimilar products, the incorporation of sophisticated data analysis techniques, and a stronger emphasis on maintaining robust supply chain capabilities.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

What Are the Key Growth Drivers Fueling the Biologics Outsourcing Market Expansion?
Projected increases in cancer incidence are anticipated to serve as a key catalyst for the expansion of the market for outsourcing biologics services in the coming period. Cancer, which encompasses a wide spectrum of ailments arising from the uncontrolled multiplication of abnormal cells that breach normal tissue confines, potentially extending to distant sites or infiltrating adjacent areas within nearly any bodily organ or tissue, heavily relies on biologics outsourcing. This external support delivers essential specialized proficiency, necessary capacity, and dedicated facilities required for advancing, producing, and supplying biologic treatments-such as monoclonal antibodies, immunotherapies, and other precision biologics utilized in identifying, managing, and treating diverse forms of malignancy-for clinical deployment. To illustrate the scale, the US dataset from the National Center for Biotechnology Information, a governmental body situated in the US, indicated an anticipated 1,958,310 new cancer diagnoses and an estimated 609,820 fatalities in the United States for 2023, based on data available in January 2023. Looking ahead, projections estimate that by the year 2040, the annual occurrence of new cancer cases will climb to 29.5 million worldwide, with associated mortality reaching 16.4 million. Consequently, this upward trend in cancer occurrences is directly fueling the expansion trajectory of the biologics outsourcing industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

What Are the Key Trends Driving Biologics Outsourcing Market Growth?
A significant current favoring the expansion of the biologics outsourcing sector involves advancements in biologic therapies. Leading entities within this outsourcing space are incorporating novel technological approaches to solidify their market standing. A prime example illustrating this shift occurred in February 2022 when Abzena, an American contract development and manufacturing organization, alongside Alira Health, a United States healthcare enterprise, and Oncodesign, a French biopharmaceutical firm, initiated DRIVE-Biologics, a collaborative group focused on advancing biologic therapeutic discovery and subsequent development projects. This joint venture furnishes comprehensive services spanning the entire spectrum, beginning with the initial biological identification stage up through clinical trials and eventual large-scale production. This alliance, integrating expertise across critical areas like molecular design suitability, validation through preclinical pharmacology and specialized imaging, safety testing, clinical strategy formulation, and final commercial manufacturing, is intended to optimize data exchange and project output, thereby mitigating risks inherent in biologic product development. Furthermore, participants in this arrangement will benefit from access to specialized knowledge covering every phase of the drug discovery and development continuum, encompassing design, preclinical assessment, clinical testing, and the crucial area of chemistry, manufacturing, and control.

How Is the Biologics Outsourcing Market Segmented?
The biologics outsourcingmarket covered in this report is segmented -

1) By Product Type: Antibodies; Recombinant; Vaccines; Protein; Other Products
2) By Source: Human; Microbial; Other Source
3) By Application: Oncology; Cellular And Gene Therapy; Blood And Blood-Related Products Development; Vaccine Development; Stem Cell Research; Other Applications
4) By End User: Pharmaceutical Industries; Biotechnology Industries; Contract Development And Manufacturing Organization(CDMO)

Subsegments:
1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies
2) By Recombinant: Recombinant Proteins; Recombinant DNA Products
3) By Vaccines: Therapeutic Vaccines; Preventive Vaccines
4) By Protein: Enzymes; Hormones; Cytokines
5) By Other Products: Gene Therapies; Cell Therapies; Biosimilars

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp

Which Companies Are Leading the Charge in Biologics Outsourcing Market Innovation?
Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Which Regions Are Leading the Global Biologics Outsourcing Market in Revenue?
North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12573

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.